Trials
Registered trials that could change what is known. Status and completion dates are read from ClinicalTrials.gov and every change is kept, including dates that slip.
01Enrolls people without obesity
33 trials
- Dulaglutide and Insulin MicrosecretiON in Type 1 DiabetesNCT03668470 · Completed · Phase 2 · 45 participants · Primary completion 2021-02-03
population of special interest (non-obese / healthy / non-diabetic)
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersNCT03835013 · Completed · NA · 26 participants · Primary completion 2021-11-01 · BMI 18 or higher
non-weight indication: cardiovascular
- Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.NCT04969627 · Completed · Phase 4 · 60 participants · Primary completion 2022-01-04 · BMI 24 or higher
non-weight indication: endocrine, other_emerging
- GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)NCT04876027 · Completed · Phase 4 · 68 participants · Primary completion 2022-04-30 · BMI 24 or higher
non-weight indication: endocrine, other_emerging
- Semaglutide Use in Elderly Obese PatientsNCT05302596 · Completed · Results posted · Phase 2 · 16 participants · Primary completion 2023-10-23 · BMI 30 or higher
non-weight indication: lean_mass, aging
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNCT05140694 · Unknown · Phase 4 · 135 participants · Primary completion 2024-06-30 · BMI 23 or higher
non-weight indication: liver
- Liraglutide Effects on Epicardial Fat Inflammatory GenesNCT03260881 · Completed · Results posted · Phase 4 · 38 participants · Primary completion 2024-09-05 · BMI 10 or higher
non-weight indication: inflammation, cardiovascular
- Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueNCT05751720 · Unknown · Phase 1, Phase 2 · 30 participants · Primary completion 2024-10 · BMI 19 or higher
non-weight indication: liver, addiction
- Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT04971785 · Completed · Results posted · Phase 2 · 457 participants · Primary completion 2024-11-12 · BMI 23 or higher
non-weight indication: liver, addiction
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296 · Completed · Phase 3 · 279 participants · Primary completion 2025-11-18 · BMI 27 or higher
non-weight indication: rheumatologic
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · Completed · NA · 396 participants · Primary completion 2025-12-31 · BMI 19 or higher
non-weight indication: cognition
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · Completed · Phase 3 · 281 participants · Primary completion 2026-01-08 · BMI 27 or higher
non-weight indication: rheumatologic
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · Completed · Phase 3 · 537 participants · Primary completion 2026-01-22 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
- GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 DiabetesNCT06630585 · Recruiting · Phase 3 · 42 participants · Primary completion 2026-06 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
- Semaglutide for Helping Opioid RecoveryNCT06639464 · Recruiting · Phase 2 · 46 participants · Primary completion 2026-08-31
non-weight indication: addiction
- Semaglutide in Auto-HSCTNCT06449625 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2026-12-31 · BMI 18 or higher
non-weight indication: inflammation
- A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesNCT06894784 · Recruiting · Phase 3 · 36 participants · Primary completion 2027-01 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · Not yet recruiting · Phase 4 · 112 participants · Primary completion 2027-04 · BMI 30 or higher
non-weight indication: cardiovascular
- GLP-1R Agonist Treatment for Opioid Use DisorderNCT06548490 · Recruiting · Phase 2 · 200 participants · Primary completion 2027-04-30 · BMI 18 or higher
non-weight indication: addiction
- Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · Not yet recruiting · Phase 2 · 120 participants · Primary completion 2027-11-30 · BMI 21 or higher
non-weight indication: kidney
- Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideNCT06657209 · Recruiting · Phase 4 · 104 participants · Primary completion 2027-12-15
population of special interest (non-obese / healthy / non-diabetic)
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · Not yet recruiting · Phase 4 · 116 participants · Primary completion 2027-12-31 · BMI 24 or higher
non-weight indication: cardiovascular
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNCT07713992 · Not yet recruiting · NA · 72 participants · Primary completion 2027-12-31 · BMI 24 or higher
non-weight indication: liver, addiction
- Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 DiabetesNCT07558863 · Recruiting · Phase 4 · 60 participants · Primary completion 2028-03-30 · BMI 24 or higher
non-weight indication: cardiovascular
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · Recruiting · Phase 3 · 350 participants · Primary completion 2028-04 · BMI 27 or higher
non-weight indication: rheumatologic
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · Recruiting · Phase 3 · 290 participants · Primary completion 2028-05 · BMI 27 or higher
non-weight indication: rheumatologic
- Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248 · Not yet recruiting · Phase 3 · 15 participants · Primary completion 2028-07-31 · BMI 22 or higher
non-weight indication: addiction
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Not yet recruiting · Phase 2, Phase 3 · 60 participants · Primary completion 2028-08-31 · BMI 24 or higher
non-weight indication: liver
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · Not yet recruiting · Phase 4 · 820 participants · Primary completion 2029-02-28 · BMI 24 or higher
non-weight indication: kidney
- Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNCT07781150 · Not yet recruiting · Phase 2 · 128 participants · Primary completion 2029-06-30 · BMI 24 or higher
non-weight indication: cancer
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · Recruiting · Phase 3 · 2000 participants · Primary completion 2029-07-01 · BMI 10 or higher
non-weight indication: cardiovascular, kidney
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)NCT07083154 · Recruiting · Phase 3 · 420 participants · Primary completion 2029-08-01 · BMI 20 or higher
non-weight indication: cognition, dementia, alzheimers
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIVNCT07221214 · Recruiting · Phase 2 · 200 participants · Primary completion 2029-10-31 · BMI 23 or higher
non-weight indication: cardiovascular, addiction, other_emerging
02Changes
Recent registry changes
No changes recorded.